Nature Communications (Feb 2024)

The liver and muscle secreted HFE2-protein maintains central nervous system blood vessel integrity

  • Xue Fan Wang,
  • Robin Vigouroux,
  • Michal Syonov,
  • Yuriy Baglaenko,
  • Angeliki M. Nikolakopoulou,
  • Dene Ringuette,
  • Horea Rus,
  • Peter V. DiStefano,
  • Suzie Dufour,
  • Alireza P. Shabanzadeh,
  • Seunggi Lee,
  • Bernhard K. Mueller,
  • Jason Charish,
  • Hidekiyo Harada,
  • Jason E. Fish,
  • Joan Wither,
  • Thomas Wälchli,
  • Jean-François Cloutier,
  • Berislav V. Zlokovic,
  • Peter L. Carlen,
  • Philippe P. Monnier

DOI
https://doi.org/10.1038/s41467-024-45303-1
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Liver failure causes breakdown of the Blood CNS Barrier (BCB) leading to damages of the Central-Nervous-System (CNS), however the mechanisms whereby the liver influences BCB-integrity remain elusive. One possibility is that the liver secretes an as-yet to be identified molecule(s) that circulate in the serum to directly promote BCB-integrity. To study BCB-integrity, we developed light-sheet imaging for three-dimensional analysis. We show that liver- or muscle-specific knockout of Hfe2/Rgmc induces BCB-breakdown, leading to accumulation of toxic-blood-derived fibrinogen in the brain, lower cortical neuron numbers, and behavioral deficits in mice. Soluble HFE2 competes with its homologue RGMa for binding to Neogenin, thereby blocking RGMa-induced downregulation of PDGF-B and Claudin-5 in endothelial cells, triggering BCB-disruption. HFE2 administration in female mice with experimental autoimmune encephalomyelitis, a model for multiple sclerosis, prevented paralysis and immune cell infiltration by inhibiting RGMa-mediated BCB alteration. This study has implications for the pathogenesis and potential treatment of diseases associated with BCB-dysfunction.